Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2003 Jul;47(7):2362-5.
doi: 10.1128/AAC.47.7.2362-2365.2003.

In vitro selection and characterization of Bacillus anthracis mutants with high-level resistance to ciprofloxacin

Lance B Price  1 , Amy Vogler, Talima Pearson, Joseph D Busch, James M Schupp, Paul Keim
Affiliations

In vitro selection and characterization of Bacillus anthracis mutants with high-level resistance to ciprofloxacin

Lance B Price et al. Antimicrob Agents Chemother. 2003 Jul.

Abstract

Mutants of attenuated Bacillus anthracis with high-level ciprofloxacin resistance were isolated using a three-step in vitro selection. Ciprofloxacin MICs were 0.5 micro g/ml for first-step mutants, which had one of two gyrA quinolone resistance-determining region (QRDR) mutations. Ciprofloxacin MICs were 8 and 16 microg/ml for second-step mutants, which had one of three parC QRDR mutations. Ciprofloxacin MICs for third-step mutants were 32 and 64 microg/ml. Mutants for which MICs were 64 microg/ml had one of two additional mutations within the gyrA QRDR or one of two mutations within the gyrB QRDR. Mutants for which MICs were 32 microg/ml had no additional target modifications but showed evidence of enhanced ciprofloxacin efflux.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Effect of INF271 on the susceptibility of third-step, high-level CIP-resistant B. anthracis mutants. S2-1 is the parent strain for the third-step mutants; S3-1, -3, -4, -5, -7, -12, -14, -15, and -17 are third-step mutants with no additional gyrase or topoisomerase mutations. S3-6, -8, -11, and -16 are third-step mutants with additional gyrase mutations. ΔΔ, Bacillus subtilis with inactivated blt and bmr transporter genes; ΔΔNA, B. subtilis strain ΔΔ with a functional NorA transporter from the plasmid expression vector pBEV.
See this image and copyright information in PMC

References

    1. Ahmed, M., L. Lyass, P. N. Markham, S. S. Taylor, N. Vazquez-Laslop, and A. A. Neyfakh. 1995. Two highly similar multidrug transporters of Bacillus subtilis whose expression is differentially regulated. J. Bacteriol. 177:3904-3910. - PMC - PubMed
    1. Brook, I., T. B. Elliott, H. I. Pryor II, T. E. Sautter, B. T. Gnade, J. H. Thakar, and G. B. Knudson. 2001. In vitro resistance of Bacillus anthracis Sterne to doxycycline, macrolides and quinolones. Int. J. Antimicrob. Agents 18:559-562. - PubMed
    1. Brook, I. 2002. The prophylaxis and treatment of anthrax. Int. J. Antimicrob. Agents 20:320-325. - PubMed
    1. Bryskier, A. 2002. Bacillus anthracis and antimicrobial agents. Clin. Microbial. Infect. 8:467-478. - PubMed
    1. Cavallo, J. D., F. Ramisse, M. Girardet, J. Vaissaire, M. Mock, and E. Hernandez. 2002. Antibiotic susceptibilities of 96 isolates of Bacillus anthracis isolated in France between 1994 and 2000. Antimicrob. Agents Chemother. 46:2307-2309. - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources